Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acotiamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acotiamide SCHEMBL29362154 | 1.00 | ACHE (0.98) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL6968566 | 0.99 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL28293346 | 0.98 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL1043131 | 0.98 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL30872102 | 0.98 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6973893 | 0.94 | ACHE (0.91) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6975742 | 0.94 | ACHE (0.91) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL28208032 | 0.94 | ACHE (0.86) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL27944898 | 0.93 | ACHE (0.88) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6963022 | 0.92 | ACHE (0.86) | ACHELMNANPSR1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116406355-B | P38 alpha mitogen-activated protein kinase inhibitors | GEN1E生命科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250353826-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404259-B2 | Inhibitors of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | GEN1E LIFESCIENCES INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250129038-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-04-24 | — | — | US | disclosed |
| WO-2025085745-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | GENIE LIFESCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240228447-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-11248030-B2 | Dual IL-2R and IL-7R binding compounds | MEDIKINE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-113979908-A | Acotiamide hydrochloride impurity and preparation method thereof | 南京海纳医药科技股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113640426-A | Method for determining amine residue in acotiamide hydrochloride raw material medicine by gas chromatography | 宜昌人福药业有限责任公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113418995-A | Detection method of related substances in acotiamide hydrochloride | 南京一诺医药科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113292512-A | Acotiamide hydrochloride impurity and preparation method thereof | 南京海纳医药科技股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-107228906-B | Method for determining residual quantity of N, N-diisopropylethylenediamine in acotiamide bulk drug by using gas chromatograph | 中美华世通生物医药科技(武汉)股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-107228909-B | Method for measuring acotiamide hydrochloride raw material medicine and related substances in preparation thereof by using HPLC | 中美华世通生物医药科技(武汉)股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-109776447-B | Industrial production method of acotiamide hydrochloride | 常州市阳光药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-103622929-A | Acotiamide hydrochloride sustained release tablet and preparation method thereof | ANHUI PIONEER PHARMACEUTICAL CO LTD | 2014-03-12 | — | — | CN | disclosed |
| CN-103610657-A | Acotiamide sustained-release preparation | BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2014-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | REN, PKD1, DSP | ACHE 4033/4885LMNA 595/4885NPSR1 235/4885 |
| US-20250353826-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, MAP3K19 | ACHE 4580/4885LMNA 4106/4885NPSR1 3538/4885 |
| US-12404259-B2 | Inhibitors of extracellular signal-regulated kinase | MAP3K20, MAP3K6, MAP3K19 | ACHE 4580/4885LMNA 4106/4885NPSR1 3538/4885 |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, CDC42BPG | ACHE 2839/4885LMNA 2164/4885NPSR1 2027/4885 |
| US-20240228447-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPKAPK2 | ACHE 3682/4885LMNA 679/4885NPSR1 3187/4885 |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | REN, PKD1, DSP | ACHE 4033/4885LMNA 595/4885NPSR1 235/4885 |
| US-20250129038-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, MAP3K19 | ACHE 4580/4885LMNA 4106/4885NPSR1 3538/4885 |
| US-11248030-B2 | Dual IL-2R and IL-7R binding compounds | IL2RA, IL2, IL23R | ACHE 4662/4885LMNA 4320/4885NPSR1 775/4885 |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | CDC42BPG, GRK3, ERBB2 | ACHE 4863/4885LMNA 3861/4885NPSR1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.